New drug duo aims to shrink Hard-to-Treat tumors
Disease control
Recruiting now
This study tests a new drug called ADG126 combined with pembrolizumab (a standard immunotherapy) in people with advanced or metastatic solid tumors that have not responded to other treatments. The goal is to find the safest dose and see if the combination can shrink tumors. About…
Phase: PHASE1, PHASE2 • Sponsor: Adagene Inc • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC